ANI Pharmaceuticals completed the acquisition of Alimera Sciences for $453m.

ANI Pharmaceuticals, a diversified biopharmaceutical company, completed the acquisition of Alimera Sciences, a global pharmaceutical company, for $453m. "We are pleased to have reached this agreement with ANI, which we believe recognizes the value we have created at Alimera and creates compelling value for our shareholders. ANI and Alimera share a common mission of putting patients first, and this complementary transaction creates a bigger platform to leverage our global infrastructure and outstanding team. I would like to thank Alimera employees, past and present, for always finding a way to help patients maintain better vision longer. We look forward to working with ANI to complete this transaction and help grow its presence in the ophthalmology segment," Rick Eiswirth, Alimera President and CEO.